TFX

Teleflex's stock price has been impacted by several events over the past six months. The company reported a significant GAAP loss in Q3 2025 due to an impairment charge and lowered its full-year revenue growth guidance, leading to a negative market reaction. Teleflex missed revenue and adjusted EPS expectations in Q4 2025, contributing to a stock drop. Teleflex announced the global implementation of Demand Planning and Supply Planning on the o9 platform. The Hart-Scott-Rodino waiting period for the OEM business divestiture expired, while divestitures of Acute Care and Interventional Urology businesses received Federal Trade Commission Second Requests. Teleflex reported Q1 2026 financial results that surpassed expectations, leading to a stock price jump. Management flagged near-term margin pressure and supplier recalls. Teleflex announced plans to begin opportunistic share repurchases in Q2 2026.